Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Revenue | $361.4M | $831.6M | $1.61B | $2.74B |
| Cost of revenue | $284.7M | $666.3M | $1.41B | $2.32B |
| Gross profit | $76.7M | $165.2M | $199.0M | $421.7M |
| Gross margin | 21.2% | 19.9% | 12.4% | 15.4% |
| R&D | $0 | $0 | $0 | $0 |
| Operating income | $10.8M | $42.6M | −$102.6M | −$89.7M |
| EBITDA | $17.6M | −$18.0M | −$48.6M | −$197.6M |
| Net income | −$29.7M | −$71.1M | −$116.7M | −$428.4M |
| Net margin | -8.2% | -8.5% | -7.3% | -15.6% |
| EPS (diluted) | -17.86 | -42.75 | -24.54 | -87.60 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds CANO.
No tracked institution reports a position in CANO as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-11-03 | 1-for-100reverse |
No one on the platform has traded CANO yet.
| $10M |
| — |
| FTRPField Trip Health Ltd. | $0.84 | +1.07% | $10M | — |
| HURATuHURA Biosciences, Inc. | $2.29 | +6.02% | $146M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.